174 related articles for article (PubMed ID: 35008396)
1. Circulating Cell-Free DNA-Based Comprehensive Molecular Analysis of Biliary Tract Cancers Using Next-Generation Sequencing.
Csoma SL; Bedekovics J; Veres G; Árokszállási A; András C; Méhes G; Mokánszki A
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008396
[TBL] [Abstract][Full Text] [Related]
2. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
[TBL] [Abstract][Full Text] [Related]
3. Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer.
Gou Q; Zhang CZ; Sun ZH; Wu LG; Chen Y; Mo ZQ; Mai QC; He J; Zhou ZX; Shi F; Cui W; Zou W; Lv L; Zhuang WH; Xu RD; Li WK; Zhang J; Du HW; Xiang JX; Wang HZ; Hou T; Li ST; Li Y; Chen XM; Zhou ZJ
ESMO Open; 2021 Dec; 6(6):100275. PubMed ID: 34653800
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA.
Astier C; Ngo C; Colmet-Daage L; Marty V; Bawa O; Nicotra C; Ngo-Camus M; Italiano A; Massard C; Scoazec JY; Smolenschi C; Ducreux M; Hollebecque A; Postel-Vinay S
Exp Hematol Oncol; 2024 Jan; 13(1):2. PubMed ID: 38191492
[TBL] [Abstract][Full Text] [Related]
5. Biliary cancer: Utility of next-generation sequencing for clinical management.
Javle M; Bekaii-Saab T; Jain A; Wang Y; Kelley RK; Wang K; Kang HC; Catenacci D; Ali S; Krishnan S; Ahn D; Bocobo AG; Zuo M; Kaseb A; Miller V; Stephens PJ; Meric-Bernstam F; Shroff R; Ross J
Cancer; 2016 Dec; 122(24):3838-3847. PubMed ID: 27622582
[TBL] [Abstract][Full Text] [Related]
6. [Molecular analysis of cell-free DNA in peripheral blood in biliary tract malignancies].
Csoma SL; Bedekovics J; Veres G; Árokszállási A; András C; Méhes G; Mokánszki A
Orv Hetil; 2022 Dec; 163(50):1982-1991. PubMed ID: 36502421
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
Yu H; Xu Y; Gao W; Li M; He J; Deng X; Xing W
Front Oncol; 2022; 12():930611. PubMed ID: 36072793
[TBL] [Abstract][Full Text] [Related]
8. Applied precision cancer medicine in metastatic biliary tract cancer.
Taghizadeh H; Müllauer L; Mader R; Prager GW
Hepatol Int; 2020 Mar; 14(2):288-295. PubMed ID: 32100259
[TBL] [Abstract][Full Text] [Related]
9. Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer.
Shen N; Zhang D; Yin L; Qiu Y; Liu J; Yu W; Fu X; Zhu B; Xu X; Duan A; Chen Z; Wang X; Cao X; Zhao T; Zhou Z; Yu L; Qin H; Fang Z; Li JY; Liu Y; Xiong L; Yuan B; Li F; Zhang Y
Oncol Rep; 2019 Aug; 42(2):549-560. PubMed ID: 31173267
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza.
Queiroz MM; Lima NF; Biachi de Castria T
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046631
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of biliary tract cancer: a target rich disease.
Jain A; Javle M
J Gastrointest Oncol; 2016 Oct; 7(5):797-803. PubMed ID: 27747093
[TBL] [Abstract][Full Text] [Related]
12. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.
Jain A; Kwong LN; Javle M
Curr Treat Options Oncol; 2016 Nov; 17(11):58. PubMed ID: 27658789
[TBL] [Abstract][Full Text] [Related]
13. Liquid Biopsy from Bile-Circulating Tumor DNA in Patients with Biliary Tract Cancer.
Han JY; Ahn KS; Kim TS; Kim YH; Cho KB; Shin DW; Baek WK; Suh SI; Jang BC; Kang KJ
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572808
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
15. Cell of origin in biliary tract cancers and clinical implications.
Moeini A; Haber PK; Sia D
JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.
Weinberg BA; Xiu J; Lindberg MR; Shields AF; Hwang JJ; Poorman K; Salem ME; Pishvaian MJ; Holcombe RF; Marshall JL; Morse MA
J Gastrointest Oncol; 2019 Aug; 10(4):652-662. PubMed ID: 31392046
[TBL] [Abstract][Full Text] [Related]
17. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
Chae YK; Davis AA; Carneiro BA; Chandra S; Mohindra N; Kalyan A; Kaplan J; Matsangou M; Pai S; Costa R; Jovanovic B; Cristofanilli M; Platanias LC; Giles FJ
Oncotarget; 2016 Oct; 7(40):65364-65373. PubMed ID: 27588476
[TBL] [Abstract][Full Text] [Related]
18. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
19. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
Ohira T; Sakai K; Matsubayashi J; Kajiwara N; Kakihana M; Hagiwara M; Hibi M; Yoshida K; Maeda J; Ohtani K; Nagao T; Nishio K; Ikeda N
Cancer Sci; 2016 Nov; 107(11):1660-1666. PubMed ID: 27575703
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
